Skip to content
DataLookout
Menu

NCT04195750

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

StatusActive, Not Recruiting
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Oct 21, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

The 49 most recent of 95 versions: 48 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Study completion pushed from Sep 17, 2026 to Nov 11, 2026
  2. Notable Eligibility criteria expanded, about 29 words Show 4 more changesShow less
    • Study completion date: Sep 17, 2026 to Oct 14, 2026
    • Secondary endpoints: details revised at 10 of 11 entries
    • Site details revised at 4 of 172 sites
    • Publications: details revised at 2 of 2 entries
  3. Minor Study sites revised (172)v94
  4. Notable Results first posted: Apr 29, 2025v93 Show 4 more changesShow less
    • Eligibility criteria revised
    • Secondary endpoints revised (11)
    • Primary endpoints revised (2)
    • Study arms: 2 to 3
  5. Minor Study completion date: Sep 17, 2025 to Sep 17, 2026v92
Show 44 earlier versionsHide 44 earlier versions
  1. Study Identification, Study Status, Referencesv91
  2. Minor Enrollment target: estimated 736 to confirmed 755
    • Primary completion date changed from estimate of Sep 17, 2025 to Apr 15, 2024
    v90
  3. Notable Eligibility criteria revisedv88
  4. Study Identification, Study Status, Outcome Measures, Referencesv87
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 172 of 172 sites
    v86
  6. Minor Site details revised at 6 of 172 sitesv85
  7. Minor Site details revised at 2 of 172 sitesv84
  8. Minor Site details revised at 1 of 172 sitesv83
  9. Minor Site details revised at 3 of 172 sitesv82
  10. Minor Site details revised at 3 of 172 sitesv81
  11. Minor Site details revised at 2 of 172 sitesv80
  12. Minor Site details revised at 3 of 172 sitesv79
  13. Minor Site details revised at 2 of 172 sitesv78
  14. Minor Site details revised at 2 of 172 sitesv77
  15. Minor Site details revised at 5 of 172 sitesv76
  16. Minor Site details revised at 7 of 172 sitesv75
  17. Minor Site details revised at 7 of 172 sitesv74
  18. Minor Site details revised at 11 of 172 sitesv73
  19. Minor Site details revised at 8 of 172 sitesv72
  20. Minor Site details revised at 5 of 172 sitesv71
  21. Minor Site details revised at 4 of 172 sitesv70
  22. Minor Study sites: 171 to 172v69
  23. Minor Site details revised at 2 of 171 sitesv68
  24. Minor Site details revised at 5 of 171 sitesv67
  25. Minor Study sites: 170 to 171v66
  26. Minor Site details revised at 4 of 170 sitesv65
  27. Minor Study sites: 168 to 170v64
  28. Minor Site details revised at 1 of 168 sitesv63
  29. Minor Study sites: 167 to 168v62
  30. Minor Study sites: 166 to 167v61
  31. Minor Study sites: 164 to 166v60
  32. Minor Study sites: 163 to 164v59
  33. Minor Study sites: 162 to 163v58
  34. Minor Study sites: 160 to 162v57
  35. Minor Study sites: 154 to 160v56
  36. Minor Study sites: 151 to 154v55
  37. Minor Study sites: 148 to 151v54
  38. Minor Study sites: 144 to 148v53
  39. Minor Study sites revised (144)v52
  40. Minor Study sites revised (144)v51
  41. Minor Site details revised at 2 of 144 sitesv50
  42. Minor Site details revised at 1 of 144 sitesv49
  43. Minor Study sites: 143 to 144v48
  44. Minor Site details revised at 2 of 143 sitesv47
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free Survival (PFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Timeframe: Up to approximately 39 months
Overall Survival (OS)
Timeframe: Up to approximately 49 months

Secondary (11)

Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
Number of Participants Who Experience One or More Adverse Events (AEs)
Number of Participants Who Discontinue Study Treatment Due to an AE
Time to True Deterioration (TTD) in Health-Related Quality-of-Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 29 and 30 Combined Score
Show 6 moreShow less
TTD in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 Score
TTD in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) Items 1-9 Score
Change From Baseline to Week 17 in the HRQoL Using the EORTC QLQ-C30 Items 29 and 30 Combined Score
Change From Baseline to Week 17 in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 Score
Change From Baseline to Week 17 in Disease Symptoms Using the FKSI-DRS Items 1-9 Score
Change From Baseline to Week 17 in Visual Analogue Scale (VAS) Score on the European Quality of Life 5 Dimension, 5-level Questionnaire (EQ-5D-5L) Health Utility Score

Arms and interventions

BelzutifanExperimental

Randomized participants received 120 mg of belzutifan orally once daily (QD), until disease progression or discontinuation.

EverolimusActive comparator

Randomized participants received 10 mg of Everolimus orally QD, until disease progression or discontinuation.

Safety Run-InExperimental

Non-Randomized participants enrolled into the Safety Run-in received up to 120 mg of belzutifan QD.

Drugs: Belzutifan, Everolimus

Sites

172 sites in 23 countries

United States 29, Japan 23, Russia 11, Italy 10, United Kingdom 9, France 8, Germany 8, Turkey (Türkiye) 8, Canada 6, Czechia 6, Hungary 6, South Korea 6, Taiwan 6, Brazil 5, Colombia 5, Spain 5, Finland 4, Hong Kong 4, Sweden 4, Ukraine 3, Chile 2, Denmark 2, Norway 2